Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 14/20 | 0.64 |
| ▸ | EGFR | P00533 | 13/20 | 0.62 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.62 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.62 |
| ▸ | RET | P07949 | 1/20 | 0.57 |
| ▸ | KIF5B | P33176 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 1/20 | 0.57 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29126703 | 0.88 | EGFR (0.58) | CSF1REGFRPDGFRBPDGFRARET | |
| SCHEMBL3112121 | 0.85 | EGFR (0.72) | CSF1REGFRPDGFRBPDGFRAKDR | |
| SCHEMBL31238168 | 0.84 | EGFR (0.71) | CSF1REGFRPDGFRBPDGFRARET | |
| SCHEMBL29126711 | 0.82 | HDAC8 (0.52) | CSF1REGFRPDGFRBPDGFRARET | |
| SCHEMBL22110372 | 0.81 | HDAC1 (0.77) | EGFRKDR | |
| SCHEMBL4074929 | 0.81 | CASP1 (0.73) | CSF1REGFRPDGFRBPDGFRAKDR | |
| SCHEMBL29126697 | 0.81 | CYP1A2 (0.76) | CSF1REGFRPDGFRBPDGFRARET | |
| SCHEMBL2259608 | 0.80 | EGFR (0.74) | EGFRPDGFRBPDGFRAKDR | |
| SCHEMBL4355365 | 0.80 | CSF1R (0.73) | CSF1REGFRPDGFRBPDGFRARET | |
| SCHEMBL29126712 | 0.79 | HDAC8 (0.49) | CSF1REGFRPDGFRBPDGFRARET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989462-B2 | 4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | MYREXIS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989462-B2 | 4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | MYREXIS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989462-B2 | 4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | MYREXIS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20080004297-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-20080004297-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-20080004297-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| EP-1833482-A2 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. (US) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006074147-A2 | NITROGEN CONTAINING BICYCLIC COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004297-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | CSF1R 3082/4885EGFR 2915/4885PDGFRB 2620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.